BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology. 2008;47:2127-2133. [PMID: 18446789 DOI: 10.1002/hep.22269] [Cited by in Crossref: 175] [Cited by in F6Publishing: 150] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Scudiero F, Valenti R, Marcucci R, Sanna GD, Gori AM, Migliorini A, Vitale R, Giusti B, De Vito E, Corda G, Paniccia R, Zirolia D, Canonico ME, Parodi G. Platelet Reactivity in Hepatitis C Virus-Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. J Am Heart Assoc 2020;9:e016441. [PMID: 32885738 DOI: 10.1161/JAHA.120.016441] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Shams F, Rafique S, Zahid S, Munir M, Idrees M, Ilyas M, Husnain T. Advances in the role of HCV nonstructural protein 5a (NS5A) of 3a genotype in inducing insulin resistance by possible phosphorylation of AKT/PKB. Sci Rep 2019;9:6150. [PMID: 30992506 DOI: 10.1038/s41598-019-42602-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Brandman D, Bacchetti P, Ayala CE, Maher JJ, Khalili M. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care. 2012;35:1090-1094. [PMID: 22399695 DOI: 10.2337/dc11-1837] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
4 Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293-1302. [PMID: 24122848 DOI: 10.1002/hep.26892] [Cited by in Crossref: 194] [Cited by in F6Publishing: 173] [Article Influence: 27.7] [Reference Citation Analysis]
5 Lin YM, Sun HY, Chiu WT, Su HC, Chien YC, Chang HA, Chong LW, Chang HC, Young KC, Bai CH, Tsao CW. Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation. Biomed Res Int 2019;2019:3102414. [PMID: 30984779 DOI: 10.1155/2019/3102414] [Reference Citation Analysis]
6 Fung TC, Artis D, Sonnenberg GF. Anatomical localization of commensal bacteria in immune cell homeostasis and disease. Immunol Rev 2014;260:35-49. [PMID: 24942680 DOI: 10.1111/imr.12186] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
7 El-Zayadi AR, Anis M. Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol 2012;18:212-24. [PMID: 22294824 DOI: 10.3748/wjg.v18.i3.212] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
8 Wursthorn K, Manns MP, Wedemeyer H. Natural history: the importance of viral load, liver damage and HCC. Best Pract Res Clin Gastroenterol 2008;22:1063-79. [PMID: 19187867 DOI: 10.1016/j.bpg.2008.11.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
9 Di Maira T, Rubin A, Puchades L, Aguilera V, Vinaixa C, Garcia M, De Maria N, Villa E, Lopez-Andujar R, San Juan F, Montalva E, Perez J, Prieto M, Berenguer M. Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. Liver Transpl. 2015;21:812-822. [PMID: 27396823 DOI: 10.1002/lt.24128] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
10 Gondeau C, Pichard-Garcia L, Maurel P. Cellular models for the screening and development of anti-hepatitis C virus agents. Pharmacol Ther. 2009;124:1-22. [PMID: 19555718 DOI: 10.1016/j.pharmthera.2009.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
11 Canavesi E, Porzio M, Ruscica M, Rametta R, Macchi C, Pelusi S, Fracanzani AL, Dongiovanni P, Fargion S, Magni P, Valenti L. Increased circulating adiponectin in males with chronic HCV hepatitis. Eur J Intern Med 2015;26:635-9. [PMID: 26293833 DOI: 10.1016/j.ejim.2015.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
12 Sommer P, Sweeney G. Functional and mechanistic integration of infection and the metabolic syndrome. Korean Diabetes J 2010;34:71-6. [PMID: 20548837 DOI: 10.4093/kdj.2010.34.2.71] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
13 Lapumnuaypol K, Pisarcik D, Putthapiban P, Sukhumthammarat W, Wijarnpreecha K, Thongprayoon C, Ungprasert P. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis. Indian J Med Res 2020;152:562-7. [PMID: 34145095 DOI: 10.4103/ijmr.IJMR_1088_18] [Reference Citation Analysis]
14 Lin YM, Sun HY, Chiu WT, Su HC, Chien YC, Chong LW, Chang HC, Bai CH, Young KC, Tsao CW. Calcitriol Inhibits HCV Infection via Blockade of Activation of PPAR and Interference with Endoplasmic Reticulum-Associated Degradation. Viruses 2018;10:E57. [PMID: 29385741 DOI: 10.3390/v10020057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Stine JG, Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL. Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C. Ann Hepatol 2017;16:215-20. [PMID: 31153414 DOI: 10.5604/16652681.1231581] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
16 Khatun M, Ray R, Ray RB. Hepatitis C virus associated hepatocellular carcinoma. Adv Cancer Res 2021;149:103-42. [PMID: 33579422 DOI: 10.1016/bs.acr.2020.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH;  Virahep-C Study Group. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology. 2011;140:469-477. [PMID: 21070775 DOI: 10.1053/j.gastro.2010.11.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
18 Hong YS, Chang Y, Ryu S, Cainzos-Achirica M, Kwon MJ, Zhang Y, Choi Y, Ahn J, Rampal S, Zhao D, Pastor-Barriuso R, Lazo M, Shin H, Cho J, Guallar E. Hepatitis B and C virus infection and diabetes mellitus: A cohort study. Sci Rep 2017;7:4606. [PMID: 28676706 DOI: 10.1038/s41598-017-04206-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
19 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes. 2014;5:586-600. [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
20 Miyachi H, Kobayashi Y, Relja B, Fujita N, Iwasa M, Gabazza EC, Takei Y. Effect of suppressor of cytokine signaling on hepcidin production in hepatitis C virus replicon cells. Hepatol Res. 2011;41:364-374. [PMID: 21348906 DOI: 10.1111/j.1872-034X.2011.00777.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
21 Hum J, Jou JH. The link between hepatitis C virus and diabetes mellitus: Improvement in insulin resistance after eradication of hepatitis C virus. Clin Liver Dis (Hoboken). 2018;11:73-76. [PMID: 30992793 DOI: 10.1002/cld.694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
22 Isom HC, McDevitt EI, Moon MS. Elevated hepatic iron: a confounding factor in chronic hepatitis C. Biochim Biophys Acta. 2009;1790:650-662. [PMID: 19393721 DOI: 10.1016/j.bbagen.2009.04.009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
23 Ocaña-Mondragón A, Mata-Marín JA, Uriarte-López M, Bekker-Méndez C, Alcalá-Martínez E, Ribas-Aparicio RM, Uribe-Noguéz LA, Rodríguez-Galindo DM, Martínez-Rodríguez ML. Effect of branched-chain amino acid supplementation on insulin resistance and quality of life in chronic hepatitis C patients. Biomed Rep 2018;8:85-90. [PMID: 29399341 DOI: 10.3892/br.2017.1012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 2012;56:1681-1687. [PMID: 22619107 DOI: 10.1002/hep.25867] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 7.9] [Reference Citation Analysis]
25 Li WC, Lee YY, Chen IC, Sun C, Chiu FH, Chuang CH. Association between the hepatitis B and C viruses and metabolic diseases in patients stratified by age. Liver Int. 2013;33:1194-1202. [PMID: 23782533 DOI: 10.1111/liv.12224] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
26 Hsu C, Liu C, Liu C, Hsu S, Chen C, Hwang J, Lai M, Chen P, Chen D, Kao J. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection: Metabolic profiles and hepatic fibrosis. Journal of Gastroenterology and Hepatology 2010;25:970-7. [DOI: 10.1111/j.1440-1746.2009.06186.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
27 Jiang S, Gavrikova TA, Pereboev A, Messina JL. Adenovirus infection results in alterations of insulin signaling and glucose homeostasis. Am J Physiol Endocrinol Metab 2010;298:E1295-304. [PMID: 20388825 DOI: 10.1152/ajpendo.00723.2009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
28 Zheng YY, Wang LF, Fan XH, Wu CH, Huo N, Lu HY, Xu XY, Wei L. Association of suppressor of cytokine signalling 3 polymorphisms with insulin resistance in patients with chronic hepatitis C. J Viral Hepat 2013;20:273-80. [PMID: 23490372 DOI: 10.1111/j.1365-2893.2012.01644.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
29 Alberstein M, Zornitzki T, Zick Y, Knobler H. Hepatitis C core protein impairs insulin downstream signalling and regulatory role of IGFBP-1 expression. J Viral Hepat. 2012;19:65-71. [PMID: 22187946 DOI: 10.1111/j.1365-2893.2011.01447.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
30 Ha M, Xia W, Tang D, Wu J, Sun L, Shen W, Huang Z, Chen X, Shan W. Hepatitis B e antigen-positive and high levels of alanine aminotransferase are associated with prevalence of metabolic syndrome in chronic HBV patients. Obes Res Clin Pract 2016;10:673-9. [PMID: 26515918 DOI: 10.1016/j.orcp.2015.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
31 Lonardo A, Loria P. The hepatitis C virus-associated dysmetabolic syndrome. Hepatology. 2008;48:1018-1019; author reply 1019. [PMID: 18756483 DOI: 10.1002/hep.22425] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
32 Chang ML, Kuo CJ, Pao LH, Hsu CM, Chiu CT. The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance. Virulence 2017;8:1255-64. [PMID: 28267407 DOI: 10.1080/21505594.2017.1300734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
33 Gu Y, Zhao J, Yao XM, Li Y. Effects of bicyclol on immunological liver fibrosis in rats. J Asian Nat Prod Res. 2010;12:388-398. [PMID: 20496196 DOI: 10.1080/10286021003789047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
34 Bortoletto G, Scribano L, Realdon S, Marcolongo M, Mirandola S, Franceschini L, Bonisegna S, Noventa F, Plebani M, Martines D. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat. 2010;17:475-480. [PMID: 19878535 DOI: 10.1111/j.1365-2893.2009.01204.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
35 Abdel Moneim A, Suleiman HA, Mahmoud B, Mabrouk D, Zaky MY, Mahmoud B. Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4. Clin Exp Med 2020;20:231-40. [PMID: 32076917 DOI: 10.1007/s10238-019-00605-3] [Reference Citation Analysis]
36 Lonardo A, Adinolfi LE, Petta S, Craxì A, Loria P. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther. 2009;7:293-308. [PMID: 19344243 DOI: 10.1586/eri.09.3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
37 Akiyama T, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Takahashi H, Ozaki I, Fujimoto K. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World J Gastroenterol. 2011;17:914-921. [PMID: 21412500 DOI: 10.3748/wjg.v17.i7.914] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
38 Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957-69. [DOI: 10.1002/hep.23046] [Cited by in Crossref: 318] [Cited by in F6Publishing: 288] [Article Influence: 26.5] [Reference Citation Analysis]
39 Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int. 2013;2013:564645. [PMID: 23956991 DOI: 10.1155/2013/564645] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
40 Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med. 2009;11:272-278. [PMID: 19627660 DOI: 10.1007/s11936-009-0028-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
41 Patergnani S, Suski JM, Agnoletto C, Bononi A, Bonora M, De Marchi E, Giorgi C, Marchi S, Missiroli S, Poletti F, Rimessi A, Duszynski J, Wieckowski MR, Pinton P. Calcium signaling around Mitochondria Associated Membranes (MAMs). Cell Commun Signal 2011;9:19. [PMID: 21939514 DOI: 10.1186/1478-811X-9-19] [Cited by in Crossref: 215] [Cited by in F6Publishing: 116] [Article Influence: 21.5] [Reference Citation Analysis]
42 Minisini R, Fabris C, Toniutto P, Pirisi M. Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infections. Expert Opinion on Medical Diagnostics 2009;3:355-70. [DOI: 10.1517/17530050902893311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Di Pietro M, Filardo S, Falasca F, Turriziani O, Sessa R. Infectious Agents in Atherosclerotic Cardiovascular Diseases through Oxidative Stress. Int J Mol Sci 2017;18:E2459. [PMID: 29156574 DOI: 10.3390/ijms18112459] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
44 Pazienza V, Vinciguerra M, Andriulli A, Mangia A. Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J Gen Virol 2010;91:1678-86. [PMID: 20357037 DOI: 10.1099/vir.0.020644-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
45 Khan M, Jahan S, Khaliq S, Ijaz B, Ahmad W, Samreen B, Hassan S. Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis. Arch Virol 2010;155:1735-53. [DOI: 10.1007/s00705-010-0797-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
46 Kukla M, Piotrowski D, Waluga M, Hartleb M. Insulin resistance and its consequences in chronic hepatitis C. Clin Exp Hepatol. 2015;1:17-29. [PMID: 28856251 DOI: 10.5114/ceh.2015.51375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
47 Choi J. Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations. Free Radic Biol Med. 2012;52:1135-1150. [PMID: 22306508 DOI: 10.1016/j.freeradbiomed.2012.01.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
48 Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes. 2014;5:52-58. [PMID: 24567801 DOI: 10.4239/wjd.v5.i1.52] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
49 Yoon S, Jung J, Kim T, Park S, Chwae YJ, Shin HJ, Kim K. Adiponectin, a downstream target gene of peroxisome proliferator-activated receptor γ, controls hepatitis B virus replication. Virology. 2011;409:290-298. [PMID: 21059469 DOI: 10.1016/j.virol.2010.10.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
50 Lee JJ, Lin MY, Chang JS, Hung CC, Chang JM, Chen HC, Yu ML, Hwang SJ. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9:e100790. [PMID: 24971499 DOI: 10.1371/journal.pone.0100790] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 11.1] [Reference Citation Analysis]
51 Guldiken N, Usachov V, Levada K, Trautwein C, Ziol M, Nahon P, Strnad P. Keratins 8 and 18 are type II acute-phase responsive genes overexpressed in human liver disease. Liver Int 2015;35:1203-12. [DOI: 10.1111/liv.12608] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
52 Beig J, Orr D, Harrison B, Gane E. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients. Liver Transpl 2018;24:1031-9. [PMID: 29577581 DOI: 10.1002/lt.25060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
53 Khoontawad J, Pairojkul C, Rucksaken R, Pinlaor P, Wongkham C, Yongvanit P, Pugkhem A, Jones A, Plieskatt J, Potriquet J, Bethony J, Pinlaor S, Mulvenna J. Differential Protein Expression Marks the Transition From Infection With Opisthorchis viverrini to Cholangiocarcinoma. Mol Cell Proteomics 2017;16:911-23. [PMID: 28232516 DOI: 10.1074/mcp.M116.064576] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
54 Zhang H, Xu H, Wu R, Yu G, Sun H, Lv J, Wang X, Chi X, Gao X, Kong F, Zhang M, Hang L, Jiang J, Pan Y, Niu J. Association of Hepatitis C and B Virus Infection with CKD and Impact of Hepatitis C Treatment on CKD. Sci Rep 2019;9:1910. [PMID: 30760762 DOI: 10.1038/s41598-018-36437-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
55 Sripa B, Mairiang E, Thinkhamrop B, Laha T, Kaewkes S, Sithithaworn P, Tessana S, Loukas A, Brindley PJ, Bethony JM. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology. 2009;50:1273-1281. [PMID: 19676135 DOI: 10.1002/hep.23134] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 9.6] [Reference Citation Analysis]
56 Seronello S, Ito C, Wakita T, Choi J. Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD+. J Biol Chem. 2010;285:845-854. [PMID: 19910460 DOI: 10.1074/jbc.m109.045740] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
57 Jackel-Cram C, Qiao L, Xiang Z, Brownlie R, Zhou Y, Babiuk L, Liu Q. Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway. J Gen Virol. 2010;91:1388-1395. [PMID: 20130133 DOI: 10.1099/vir.0.017418-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
58 Li Y, Zhao Y, Wu J. Serum HBV surface antigen positivity is associated with low prevalence of metabolic syndrome: A meta-analysis. PLoS One 2017;12:e0177713. [PMID: 28505202 DOI: 10.1371/journal.pone.0177713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
59 Raglow Z, Thoma-Perry C, Gilroy R, Wan YJ. The interaction between HCV and nuclear receptor-mediated pathways. Pharmacol Ther 2011;132:30-8. [PMID: 21620888 DOI: 10.1016/j.pharmthera.2011.05.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
60 Masarone M, Persico M. Antiviral therapy: why does it fail in HCV-related chronic hepatitis? Expert Rev Anti Infect Ther. 2011;9:535-543. [PMID: 21609265 DOI: 10.1586/eri.11.10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
61 Chen CH, Huang JF, Huang CF, Yeh ML, Yang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chuang WL, Dai CY, Yu ML. Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. Hepatol Int 2013;7:162-70. [PMID: 26201630 DOI: 10.1007/s12072-012-9388-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
62 Wu CF, Lin YL, Huang YT. Hepatitis C virus core protein stimulates fibrogenesis in hepatic stellate cells involving the obese receptor. J Cell Biochem. 2013;114:541-550. [PMID: 22961938 DOI: 10.1002/jcb.24392] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
63 Hayaishi S, Chung H, Kudo M, Ishikawa E, Takita M, Ueda T, Kitai S, Inoue T, Yada N, Hagiwara S. Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis. Dig Dis. 2011;29:326-332. [PMID: 21829025 DOI: 10.1159/000327571] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
64 Hsu CS, Liu CH, Wang CC, Tseng TC, Liu CJ, Chen CL, Chen PJ, Chen DS, Kao JH. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat. 2012;19:e48-e57. [PMID: 22239526 DOI: 10.1111/j.1365-2893.2011.01535.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
65 Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced J Med Sci. 2015;3:732-736. [PMID: 27275318 DOI: 10.3889/oamjms.2015.111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 9.7] [Reference Citation Analysis]
66 Testino G, Borro P. Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World J Hepatol. 2013;5:521-527. [PMID: 24179611 DOI: 10.4254/wjh.v5.i10.521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
67 Lee MY, Chen WC, Hsu WH, Chen SC, Lee JC. Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism. Int J Mol Sci 2019;20:E4569. [PMID: 31540136 DOI: 10.3390/ijms20184569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
68 Lebiedzinska M, Szabadkai G, Jones AW, Duszynski J, Wieckowski MR. Interactions between the endoplasmic reticulum, mitochondria, plasma membrane and other subcellular organelles. Int J Biochem Cell Biol 2009;41:1805-16. [PMID: 19703651 DOI: 10.1016/j.biocel.2009.02.017] [Cited by in Crossref: 127] [Cited by in F6Publishing: 114] [Article Influence: 10.6] [Reference Citation Analysis]
69 Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14-22. [PMID: 21115577 DOI: 10.1634/theoncologist.2010-s4-14] [Cited by in Crossref: 293] [Cited by in F6Publishing: 149] [Article Influence: 29.3] [Reference Citation Analysis]
70 Saab S, Sikavi C, Jimenez M, Viramontes M, Allen R, Challita Y, Mai M, Esmailzadeh N, Grotts J, Choi G, Durazo F, El-Kabany M, Han SH, Moreno E. Clinical Food Addiction Is Not Associated with Development of Metabolic Complications in Liver Transplant Recipients. J Clin Transl Hepatol 2017;5:335-42. [PMID: 29226100 DOI: 10.14218/JCTH.2017.00023] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
71 Uehara T, Kosyk O, Jeannot E, Bradford BU, Tech K, Macdonald JM, Boorman GA, Chatterjee S, Mason RP, Melnyk SB. Acetaminophen-induced acute liver injury in HCV transgenic mice. Toxicol Appl Pharmacol. 2013;266:224-232. [PMID: 23200774 DOI: 10.1016/j.taap.2012.11.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
72 Thoefner LB, Rostved AA, Pommergaard HC, Rasmussen A. Risk factors for metabolic syndrome after liver transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2018;32:69-77. [PMID: 28501338 DOI: 10.1016/j.trre.2017.03.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
73 Graf C, Welzel T, Bogdanou D, Vermehren J, Beckel A, Bojunga J, Friedrich-Rust M, Dietz J, Kubesch A, Mondorf A, Fischer S, Lutz T, Stoffers P, Herrmann E, Poynard T, Zeuzem S, Dultz G, Mihm U. Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis. J Clin Med 2020;9:E2702. [PMID: 32825571 DOI: 10.3390/jcm9092702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
74 Bononi A, Missiroli S, Poletti F, Suski JM, Agnoletto C, Bonora M, De Marchi E, Giorgi C, Marchi S, Patergnani S, Rimessi A, Wieckowski MR, Pinton P. Mitochondria-Associated Membranes (MAMs) as Hotspot Ca2+ Signaling Units. In: Islam MS, editor. Calcium Signaling. Dordrecht: Springer Netherlands; 2012. pp. 411-37. [DOI: 10.1007/978-94-007-2888-2_17] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
75 Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8:1017-1029. [PMID: 20870037 DOI: 10.1016/j.cgh.2010.08.026] [Cited by in Crossref: 108] [Cited by in F6Publishing: 95] [Article Influence: 9.8] [Reference Citation Analysis]
76 Parvaiz F, Manzoor S, Iqbal J, Sarkar-Dutta M, Imran M, Waris G. Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis. World J Gastroenterol. 2015;21:12361-12369. [PMID: 26604643 DOI: 10.3748/wjg.v21.i43.12361] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
77 Manzoor S, Idrees M, Ashraf J, Mehmood A, Butt S, Fatima K, Akbar H, Rehaman IU, Qadri I. Identification of ionotrophic purinergic receptors in Huh-7 cells and their response towards structural proteins of HCV genotype 3a. Virol J 2011;8:431. [PMID: 21899776 DOI: 10.1186/1743-422X-8-431] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
78 Fickert P, Thueringer A, Moustafa T, Silbert D, Gumhold J, Tsybrovskyy O, Lebofsky M, Jaeschke H, Denk H, Trauner M. The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. Lab Invest. 2010;90:844-852. [PMID: 20368698 DOI: 10.1038/labinvest.2010.61] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
79 Sekiguchi S, Kimura K, Chiyo T, Ohtsuki T, Tobita Y, Tokunaga Y, Yasui F, Tsukiyama-Kohara K, Wakita T, Tanaka T. Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver. PLoS One. 2012;7:e51656. [PMID: 23284733 DOI: 10.1371/journal.pone.0051656] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
80 Liu Q, Bengmark S, Qu S. Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis. BMC Gastroenterol 2010;10:49. [PMID: 20487553 DOI: 10.1186/1471-230X-10-49] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
81 Vespasiani-Gentilucci U, Gallo P, De Vincentis A, Galati G, Picardi A. Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J Gastroenterol. 2014;20:2825-2838. [PMID: 24659875 DOI: 10.3748/wjg.v20.i11.2825] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
82 Hsieh MH, Bair MJ, Tsai PC, Tseng KC, Lo CC, Chen CY, Kuo HT, Hung CH, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL; T-COACH investigators. Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. J Gastroenterol Hepatol 2021;36:2247-54. [PMID: 33624849 DOI: 10.1111/jgh.15469] [Reference Citation Analysis]
83 Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int. 2009;29 Suppl 1:15-18. [PMID: 19207961 DOI: 10.1111/j.1478-3231.2008.01945.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
84 El-Zayadi AR. Hepatitis C comorbidities affecting the course and response to therapy. World J Gastroenterol 2009;15:4993-9. [PMID: 19859990 DOI: 10.3748/wjg.15.4993] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
85 Bedimo R, Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Curr HIV/AIDS Rep. 2016;13:328-339. [PMID: 27595755 DOI: 10.1007/s11904-016-0333-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
86 Mohamed AA, Loutfy SA, Craik JD, Hashem AG, Siam I. Chronic hepatitis c genotype-4 infection: role of insulin resistance in hepatocellular carcinoma. Virol J. 2011;8:496. [PMID: 22044490 DOI: 10.1186/1743-422x-8-496] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
87 Benini F, Pigozzi MG, Pozzi A, Bercich L, Reggiani A, Quattrocchi D, Distefano L, Donati P, Cesana BM, Lanzini A. Elevation of serum gamma-glutamyltranspeptidase activity is frequent in chronic hepatitis C, and is associated with insulin resistance. Dig Liver Dis. 2009;41:586-590. [PMID: 19131283 DOI: 10.1016/j.dld.2008.11.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
88 Eslam M, Khattab MA, Harrison SA. Peroxisome proliferator-activated receptors and hepatitis C virus. Therap Adv Gastroenterol 2011;4:419-31. [PMID: 22043232 DOI: 10.1177/1756283X11405251] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
89 Abenavoli L, Masarone M, Peta V, Milic N, Kobyliak N, Rouabhia S, Persico M. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol 2014;20:15233-40. [PMID: 25386071 DOI: 10.3748/wjg.v20.i41.15233] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
90 Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol. 2015;7:2214-2219. [PMID: 26380047 DOI: 10.4254/wjh.v7.i19.2214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
91 Qashqari H, Al-Mars A, Chaudhary A, Abuzenadah A, Damanhouri G, Alqahtani M, Mahmoud M, El Sayed Zaki M, Fatima K, Qadri I. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance. Infect Genet Evol 2013;19:113-9. [PMID: 23831932 DOI: 10.1016/j.meegid.2013.06.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
92 Kuo YC, Chen IY, Chang SC, Wu SC, Hung TM, Lee PH, Shimotohno K, Chang MF. Hepatitis C virus NS5A protein enhances gluconeogenesis through upregulation of Akt-/JNK-PEPCK signalling pathways. Liver Int 2014;34:1358-68. [PMID: 25360475 DOI: 10.1111/liv.12389] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
93 Wu WY, Kang K, Chen SL, Chiu SY, Yen AM, Fann JC, Su C, Liu H, Lee C, Fu W, Chen H, Liou H. Hepatitis C virus infection: a risk factor for Parkinson's disease. J Viral Hepat 2015;22:784-91. [DOI: 10.1111/jvh.12392] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
94 Banerjee A, Ray RB, Ray R. Oncogenic potential of hepatitis C virus proteins. Viruses. 2010;2:2108-2133. [PMID: 21994721 DOI: 10.3390/v2092108] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
95 Huang JF, Chuang WL, Yu ML, Yu SH, Huang CF, Huang CI, Yeh ML, Hsieh MH, Yang JF, Lin ZY. Hepatitis C virus infection and metabolic syndrome---a community-based study in an endemic area of Taiwan. Kaohsiung J Med Sci. 2009;25:299-305. [PMID: 19560994 DOI: 10.1016/s1607-551x(09)70520-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
96 Michalczuk MT, Kappel CR, Birkhan O, Bragança AC, Alvares-da-Silva MR. HOMA-AD in Assessing Insulin Resistance in Lean Noncirrhotic HCV Outpatients. Int J Hepatol 2012;2012:576584. [PMID: 22848841 DOI: 10.1155/2012/576584] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
97 Dong K, Chang S, Xie Q, Zhao P, Zhang H. RNA Sequencing revealed differentially expressed genes functionally associated with immunity and tumor suppression during latent phase infection of a vv + MDV in chickens. Sci Rep 2019;9:14182. [PMID: 31578366 DOI: 10.1038/s41598-019-50561-x] [Reference Citation Analysis]
98 Lim T. Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? Hepat Med. 2014;6:113-118. [PMID: 25506251 DOI: 10.2147/hmer.s60083] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
99 Sirinawasatien A, Techasirioangkun T. The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:8814135. [PMID: 33204256 DOI: 10.1155/2020/8814135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Sripa B, Thinkhamrop B, Mairiang E, Laha T, Kaewkes S, Sithithaworn P, Periago MV, Bhudhisawasdi V, Yonglitthipagon P, Mulvenna J. Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. PLoS Negl Trop Dis. 2012;6:e1654. [PMID: 22629477 DOI: 10.1371/journal.pntd.0001654] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
101 Carvalho RF, Atta AM, de Oliveira IS, Santos TPS, Santos JPA, Schinoni MI, de Sousa-Atta MLB. Adiponectin levels and insulin resistance among patients with chronic hepatitis C. Acta Trop. 2018;178:258-263. [PMID: 29217381 DOI: 10.1016/j.actatropica.2017.12.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
102 Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. Hepatitis C and hepatic steatosis. QJM. 2010;103:293-303. [PMID: 20139103 DOI: 10.1093/qjmed/hcp192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
103 Peta V, Torti C, Milic N, Focà A, Abenavoli L. Adiponectin serum level in chronic hepatitis C infection and therapeutic profile. World J Hepatol 2015;7:44-52. [PMID: 25624996 DOI: 10.4254/wjh.v7.i1.44] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
104 Granados-Montiel J, Zúñiga J, Azocar J, Feris EJ, Terreros D, Larsen CE, Clavijo OP, Cruz-Lagunas A, Middleton D, Alper CA, Pandey JP, Yunis EJ. Interaction between immunoglobulin allotypes and NK receptor genes in diabetes post-hepatitis C virus infection. Immunobiology 2011;216:686-91. [PMID: 21281981 DOI: 10.1016/j.imbio.2010.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
105 Lefkowitch JH. Recent developments in liver pathology. Human Pathology 2009;40:445-55. [DOI: 10.1016/j.humpath.2008.12.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
106 Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol. 2013;58:1028-1041. [PMID: 23262248 DOI: 10.1016/j.jhep.2012.12.014] [Cited by in Crossref: 104] [Cited by in F6Publishing: 86] [Article Influence: 11.6] [Reference Citation Analysis]
107 Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One. 2012;7:e31527. [PMID: 22363662 DOI: 10.1371/journal.pone.0031527] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
108 Ashraf W, Manzoor S, Ashraf J, Ahmed QL, Khalid M, Tariq M, Imran M, Aziz H. Transcript analysis of P2X receptors in PBMCs of chronic HCV patients: an insight into antiviral treatment response and HCV-induced pathogenesis. Viral Immunol 2013;26:343-50. [PMID: 24116708 DOI: 10.1089/vim.2013.0044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
109 Pisonero-Vaquero S, García-Mediavilla MV, Jorquera F, Majano PL, Benet M, Jover R, González-Gallego J, Sánchez-Campos S. Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin. Lab Invest 2014;94:262-74. [PMID: 24492281 DOI: 10.1038/labinvest.2013.156] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
110 Chadt A, Al-Hasani H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pflugers Arch 2020;472:1273-98. [PMID: 32591906 DOI: 10.1007/s00424-020-02417-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 29.0] [Reference Citation Analysis]
111 Tsai WL, Chang TH, Sun WC, Chan HH, Wu CC, Hsu PI, Cheng JS, Yu ML. Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate-activated protein kinase. Oncotarget 2017;8:91928-37. [PMID: 29190886 DOI: 10.18632/oncotarget.20248] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
112 Sowole MA, Kraatz H. Electrochemical detection of hepatitis C viral NS3-4A protease. Analyst 2012;137:1120. [DOI: 10.1039/c2an15881g] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
113 Chang M, Yeh H, Tsou Y, Wang C, Cheng H, Sung C, Ho Y, Chen T, Yeh C. HCV Core-Induced Nonobese Hepatic Steatosis Is Associated With Hypoadiponectinemia and Is Ameliorated by Adiponectin Administration. Obesity 2012;20:1474-80. [DOI: 10.1038/oby.2012.45] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
114 Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, Vargas-Castrillón J, Lozano-Rodríguez T, Fernández-Bermejo M, Olcoz JL, González-Gallego J, García-Monzón C, Sánchez-Campos S. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci (Lond). 2011;120:239-250. [PMID: 20929443 DOI: 10.1042/cs20100387] [Cited by in Crossref: 82] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
115 Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol. 2016;22:1461-1476. [PMID: 26819514 DOI: 10.3748/wjg.v22.i4.1461] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 54] [Article Influence: 16.0] [Reference Citation Analysis]
116 Shengir M, Elgara M, Sebastiani G. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. World J Gastroenterol 2021;27:1959-72. [PMID: 34007133 DOI: 10.3748/wjg.v27.i17.1959] [Reference Citation Analysis]
117 Persico M, Iolascon A. Steatosis as a co-factor in chronic liver diseases. World J Gastroenterol. 2010;16:1171-1176. [PMID: 20222159 DOI: 10.3748/wjg.v16.i10.1171] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
118 Huang JF, Huang CF, Yu ML, Dai CY, Huang CI, Yeh ML, Hsieh MH, Yang JF, Hsieh MY, Lin ZY. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection. J Gastroenterol Hepatol. 2011;26:530-535. [PMID: 21332548 DOI: 10.1111/j.1440-1746.2010.06438.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
119 Parvaiz F, Manzoor S, Tariq H, Javed F, Fatima K, Qadri I. Hepatitis C virus infection: molecular pathways to insulin resistance. Virol J. 2011;8:474. [PMID: 22008087 DOI: 10.1186/1743-422x-8-474] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
120 Mankouri J, Dallas ML, Hughes ME, Griffin SD, Macdonald A, Peers C, Harris M. Suppression of a pro-apoptotic K+ channel as a mechanism for hepatitis C virus persistence. Proc Natl Acad Sci USA. 2009;106:15903-15908. [PMID: 19717445 DOI: 10.1073/pnas.0906798106] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
121 Nakajima T, Tanaka N, Li G, Hu R, Kamijo Y, Hara A, Aoyama T. Effect of bezafibrate on hepatic oxidative stress: comparison between conventional experimental doses and clinically-relevant doses in mice. Redox Rep 2010;15:123-30. [PMID: 20594415 DOI: 10.1179/174329210X12650506623807] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
122 Huang QT, Huang Q, Zhong M, Wei SS, Luo W, Li F, Yu YH. Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies. J Viral Hepat 2015;22:1033-42. [PMID: 26081198 DOI: 10.1111/jvh.12430] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
123 Rosenthal E, Cacoub P. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus. 2015;24:469-482. [PMID: 25801890 DOI: 10.1177/0961203314556140] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
124 González-Reimers E, López-Prieto J, Quintero-Platt G, Pelazas-González R, Alemán-Valls MR, Pérez-Hernández O, de-la-Vega-Prieto MJ, Gómez-Rodríguez MA, Martín-González C, Santolaria-Fernández F. Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis. World J Hepatol 2016;8:74-82. [PMID: 26783423 DOI: 10.4254/wjh.v8.i1.74] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
125 Bhutta MS, Gallo ES, Borenstein R. Multifaceted Role of AMPK in Viral Infections. Cells 2021;10:1118. [PMID: 34066434 DOI: 10.3390/cells10051118] [Reference Citation Analysis]
126 Chen J, Wang F, Zhou Y, Jiang J, Ksimu S, Zhang X, Li JZ, Niu J, Wang Q. Chronic hepatitis C virus infection impairs insulin secretion by regulation of p38δ MAPK-dependent exocytosis in pancreatic β-cells. Clin Sci (Lond) 2020;134:529-42. [PMID: 32100852 DOI: 10.1042/CS20190900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
127 Kawaguchi T, Nagao Y, Sata M. Independent factors associated with altered plasma active ghrelin levels in HCV-infected patients. Liver Int. 2013;33:1510-1516. [PMID: 23809581 DOI: 10.1111/liv.12235] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Nasheri N, Joyce M, Rouleau Y, Yang P, Yao S, Tyrrell DL, Pezacki JP. Modulation of fatty acid synthase enzyme activity and expression during hepatitis C virus replication. Chem Biol. 2013;20:570-582. [PMID: 23601646 DOI: 10.1016/j.chembiol.2013.03.014] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
129 Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother. 2011;12:2215-2234. [PMID: 21883025 DOI: 10.1517/14656566.2011.597742] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
130 Parvaiz F, Manzoor S, Iqbal J, McRae S, Javed F, Ahmed QL, Waris G. Hepatitis C virus nonstructural protein 5A favors upregulation of gluconeogenic and lipogenic gene expression leading towards insulin resistance: a metabolic syndrome. Arch Virol. 2014;159:1017-1025. [PMID: 24240483 DOI: 10.1007/s00705-013-1892-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
131 Boeckmans J, Rombaut M, Demuyser T, Declerck B, Piérard D, Rogiers V, De Kock J, Waumans L, Magerman K, Cartuyvels R, Rummens JL, Rodrigues RM, Vanhaecke T. Infections at the nexus of metabolic-associated fatty liver disease. Arch Toxicol 2021;95:2235-53. [PMID: 34027561 DOI: 10.1007/s00204-021-03069-1] [Reference Citation Analysis]
132 Aoki YH, Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Waguri N, Igarashi K, Sugitani S, Takahashi T, Ishikawa T. Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C. Hepatol Res. 2011;41:118-125. [PMID: 21269381 DOI: 10.1111/j.1872-034x.2010.00749.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
133 Gobeil Odai K, O'Dwyer C, Steenbergen R, Shaw TA, Renner TM, Ghorbani P, Rezaaifar M, Han S, Langlois MA, Crawley AM, Russell RS, Pezacki JP, Tyrrell DL, Fullerton MD. In Vitro Hepatitis C Virus Infection and Hepatic Choline Metabolism. Viruses 2020;12:E108. [PMID: 31963173 DOI: 10.3390/v12010108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
134 González-Reimers E, Quintero-Platt G, Rodríguez-Gaspar M, Alemán-Valls R, Pérez-Hernández O, Santolaria-Fernández F. Liver steatosis in hepatitis C patients. World J Hepatol. 2015;7:1337-1346. [PMID: 26052379 DOI: 10.4254/wjh.v7.i10.1337] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
135 Rahman SM, Qadri I, Janssen RC, Friedman JE. Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J Lipid Res. 2009;50:2193-2202. [PMID: 19502591 DOI: 10.1194/jlr.m800633-jlr200] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
136 Corbetta S, Redaelli A, Pozzi M, Bovo G, Ratti L, Redaelli E, Pellegrini C, Beck-Peccoz P, Spada A. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection. Eur J Clin Invest. 2011;41:898-905. [PMID: 21539538 DOI: 10.1111/j.1365-2362.2011.02498.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
137 Wang Q, Chen J, Wang Y, Han X, Chen X. Hepatitis C virus induced a novel apoptosis-like death of pancreatic beta cells through a caspase 3-dependent pathway. PLoS One. 2012;7:e38522. [PMID: 22675572 DOI: 10.1371/journal.pone.0038522] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
138 Baid-Agrawal S, Frei U, Reinke P, Schindler R, Kopp MA, Martus P, Berg T, Juergensen JS, Anker SD, Doehner W. Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients. Am J Transplant. 2009;9:2777-2784. [PMID: 19845589 DOI: 10.1111/j.1600-6143.2009.02843.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
139 López-Prieto J, González-Reimers E, Alemán-Valls MR, de la Vega-Prieto MJ, Abreu-González P, Pelazas-González R, Hernández-Luis R, Jorge-Ripper C, Santolaria-Fernández F. Iron and proinflammatory cytokines in chronic hepatitis C virus infection. Biol Trace Elem Res 2013;155:5-10. [PMID: 23892696 DOI: 10.1007/s12011-013-9760-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
140 Haykal M, Matsumori A, Saleh A, Fayez M, Negm H, Shalaby M, Bassuony S. Diagnosis and treatment of HCV heart diseases. Expert Rev Cardiovasc Ther 2021;19:493-9. [PMID: 33861939 DOI: 10.1080/14779072.2021.1917383] [Reference Citation Analysis]
141 Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, Smith R, Leeson B, Beard R, Lamb JR, Lim L, Mao M, Dai H, Luk JM. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol. 2010;6:402. [PMID: 20739924 DOI: 10.1038/msb.2010.58] [Cited by in Crossref: 126] [Cited by in F6Publishing: 125] [Article Influence: 12.6] [Reference Citation Analysis]
142 Bhattacharya A, Hegazy AN, Deigendesch N, Kosack L, Cupovic J, Kandasamy RK, Hildebrandt A, Merkler D, Kühl AA, Vilagos B, Schliehe C, Panse I, Khamina K, Baazim H, Arnold I, Flatz L, Xu HC, Lang PA, Aderem A, Takaoka A, Superti-Furga G, Colinge J, Ludewig B, Löhning M, Bergthaler A. Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage. Immunity 2015;43:974-86. [PMID: 26588782 DOI: 10.1016/j.immuni.2015.10.013] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
143 Angelico F, Francioso S, Del Ben M, Feole K, Carbone M, Pignatelli P, Violi F, Angelico M. Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Aliment Pharmacol Ther. 2009;30:444-451. [PMID: 19493257 DOI: 10.1111/j.1365-2036.2009.04055.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
144 Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24:336-345. [PMID: 19335784 DOI: 10.1111/j.1440-1746.2009.05789.x] [Cited by in Crossref: 189] [Cited by in F6Publishing: 173] [Article Influence: 15.8] [Reference Citation Analysis]
145 Hsu CS, Liu WL, Li Q, Lowey B, Hertz L, Chao YC, Liang TJ, Chen DS, Kao JH. Hepatitis C virus genotypes 1-3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytes. J Formos Med Assoc 2020;119:1382-95. [PMID: 32284164 DOI: 10.1016/j.jfma.2020.03.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Hashemi SM, van der Poorten D, Barrera F, Bandara P, Lux O, Kench J, George J. Oxidative stress is closely associated with insulin resistance in genotypes 1 and 3 chronic hepatitis C. Hepatol Int 2013;7:516-23. [PMID: 26201783 DOI: 10.1007/s12072-012-9400-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
147 Shiffman ML, Gunn NT. Impact of hepatitis C virus therapy on metabolism and public health. Liver Int 2017;37 Suppl 1:13-8. [PMID: 28052632 DOI: 10.1111/liv.13282] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
148 Birkenfeld S, Dreiher J, Weitzman D, Cohen AD. A study on the association with hepatitis B and hepatitis C in 1557 patients with lichen planus. J Eur Acad Dermatol Venereol. 2011;25:436-440. [PMID: 20666875 DOI: 10.1111/j.1468-3083.2010.03809.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
149 Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009;50:1702-8. [PMID: 19845037 DOI: 10.1002/hep.23206] [Cited by in Crossref: 109] [Cited by in F6Publishing: 98] [Article Influence: 9.1] [Reference Citation Analysis]
150 Carreño V. Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy. Aliment Pharmacol Ther 2014;39:148-62. [PMID: 24279580 DOI: 10.1111/apt.12562] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]